

## Table of contents

S. No.	Particular	Page No.
1	Declaration by student	i
2	Certificate by the Supervisor/ Co-Supervisor	ii-iii
3	Certificate of Plagiarism	iv
4	Anti-plagiarism Software Report of Ph.D. Thesis	-
5	Certificate of Successful Completion of Viva-Voce of Ph.D.	v
6	Undertaking for Submission OF Ph.D. Thesis	vi
7	Acknowledgments	vii
8	List of Figures	x-xi
9	List of Tables	xii
10	Abbreviations	xiii-xvii
11	<b>Chapter 1. Introduction</b>	1-10
12	<b>Chapter 2. Review of Literature</b>	11-84
13	<b>Chapter 3. Materials and Methods</b>	85-94
14	<b>3.1. <i>In-silico</i> Screening</b>	86-90
15	<b>3.1.1.</b> Data collection and preparation of target proteins	86
16	<b>3.1.2.</b> Data collection and preparation of ligands library	87
17	<b>3.1.3.</b> Grid generation and virtual screening	87-88
18	<b>3.1.4.</b> <i>MmpL</i> 11D2 (4YOL)	87
19	<b>3.1.5.</b> <i>GltT2</i> (4FIX)	88
20	<b>3.1.6.</b> <i>MurB</i> (5JZX)	88
21	<b>3.1.7.</b> Identification of ADMET and Pharmacophore Characteristics	89
22	<b>3.1.8.</b> MDS-Molecular Dynamics Simulation of The Receptor-Ligand Complexes	89-90
23	<b>3.2. <i>In-vitro</i> Validation</b>	90-94
24	<b>3.2.1.</b> Bacterial Strain and Growth Conditions	91
25	<b>3.2.2.</b> Anti-mycobacterial Activity Against Non-Pathogenic <i>Mycobacterium</i> Species	91-92

26	<b>3.2.3.</b> Evaluation of MIC Against Non-Pathogenic Strains of <i>Mycobacterium</i>	92
27	<b>3.2.4.</b> Antimycobacterial Activity Using BACTEC Radiometric Assay (Virulent and Clinical strains)	93-94
28	<b>Chapter 4. Results</b>	95-177
29	<b>4.1. In-silico</b> Screening	95-173
30	<b>4.1.1.</b> Virtual screening of chemical repositories	95-159
31	<b>4.1.2.</b> Mycobacterial Mycolic Acid membrane protein <i>MmpL</i> 11D2 (4YOL)	95-107
32	<b>4.1.3.</b> Identified compounds- <i>MmpL</i> 11D2 interactions	98-107
33	<b>4.1.4.</b> Mycobacterial Arabinogalactan membrane protein <i>GltT2</i> (4FIX)	107-133
34	<b>4.1.5.</b> Identified compounds- <i>GltT2</i> interactions	112-133
35	<b>4.1.6.</b> Mycobacterial Peptidoglycan membrane protein <i>MurB</i> (5JZX)	133-159
36	<b>4.1.7.</b> Identified compounds- <i>MurB</i> interactions	137-159
37	<b>4.1.8.</b> ADMET and Pharmacophore Characteristics	160-163
38	<b>4.1.9.</b> Molecular Dynamics (MD) Simulations of Receptor-Ligand complexes	164-173
39	<b>4.2. In-vitro</b> Validation	173-177
40	<b>Chapter 5. Discussion</b>	178-187
41	<b>Chapter 6. Conclusion</b>	188-189
42	<b>Chapter 7. Summary</b>	190-193
43	<b>References</b>	194-212
44	<b>Appendices</b>	213-250
45	<b>One published research paper</b>	251-260
46	<b>One published review paper</b>	261-277
47	<b>Certificate of two papers presented in Conferences/Seminar</b>	278